So the first type is to base a retinal vein occlusion based on the parts of the retina that it's involving. So you can have something called a central retinal vein occlusion, and that's where you ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Considering taking supplements to treat retinal vein occlusion? Below is a list of common natural remedies used to treat or reduce the symptoms of retinal vein occlusion. Follow the links to read ...

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder with potential risk of blindness. CRVO can be categorized into two distinct entities – non-ischemic and ischemic.

In this expert perspective, Manjot K. Gill, MD, discusses faricimab for the management of retinal vein occlusion.

The FDA has accepted Regeneron Pharmaceuticals’ sBLA for Eylea HD (aflibercept) injection 8mg for priority review.

for aflibercept injection 8mg for the treatment of macular edema following retinal vein occlusion (RVO) and monthly dosing across all approved indications. The sBLA was supported by data from the ...

We evaluated the efficacy and safety of DEX implant in the treatment of macular edema secondary to retinal vein occlusion (RVO ... edema secondary to branch or central RVO (BRVO, CRVO) who ...